Marbocyl
Disclaimer: This site has been created by www.MedicAnimal.com for information purposes only. MedicAnimal is a proud retailer of Marbocyl but is not affiliated with or related to the manufacturer of Marbocyl and the contents of this site are neither sponsored or endorsed by the manufacturer of Marbocyl.
Buy Marbocyl
Introduction
1. Marbocyl P 5mg, 20mg, 80mg tablets
2. Marbocyl 10%
Presentation
1. Marbocyl P 5mg, 20mg, 80mg tablets
Tablets
Three strengths are available.
Marbocyl P 5 mg containing 5 mg marbofloxacin. For use in dogs and cats.
Marbocyl P 20 mg containing 20 mg marbofloxacin.For use in dogs.
Marbocyl P 80 mg containing 80 mg marbofloxacin. For use in dogs.
2. Marbocyl 10%
Solution for Injection. Each 100ml contains marbofloxacin 10g, monothioglycerol 0.1g, metacresol 0.2g and disodium edetate 0.01g
Uses
1. Marbocyl P 5mg, 20mg, 80mg tablets
In Dogs
Marbocyl is indicated for the treatment of skin and soft tissue infections (skin fold pyoderma, impetigo, folliculitis, furunculosis, cellulitis), for the treatment of urinary tract infections associated or not with prostatitis and respiratory tract infections, caused by susceptible strains of organisms.
In Cats (Marbocyl P 5mg Tablet only)
Marbocyl is indicated for the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper respiratory tract infections caused by susceptible strains of organisms.
2. Marbocyl 10%
In cattle: Indicated in the treatment of respiratory infections caused by susceptible strains of organisms. It is also indicated in the treatment of acute E.coli mastitis.
In pigs: Indicated in the treatment of Metritis Mastitis Agalactia syndrome caused by susceptible strains of organisms.
Dosage & administration
1. Marbocyl P 5mg, 20mg, 80mg tablets
The recommended dose rate is 2 mg/kg per day in a single daily administration.
In dogs for the treatment of skin and soft tissue infections, treatment duration is at least five days. Depending on the course of the disease it may be extended up to 40 days. In urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease it may be extended up to 28 days. In respiratory infections, treatment duration is at least 7 days and, depending on the course of the disease, may be extended up to 21 days.
In cats for the treatment of skin and soft tissue infections, treatment duration is 3–5 days. For upper respiratory infections, treatment duration is 5 days.
2. Marbocyl 10%
The recommended dose rate is 2mg/kg/day (1ml/50kg) in a single daily injection by intramuscular, subcutaneous or intravenous routes in cattle and by intramuscular route in pigs.
Treatment durations are 3 days in pigs and 3 to 5 days in cattle.
In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.
Price comparison
Contra-indications, warnings, etc.
1. Marbocyl P 5mg, 20mg, 80mg tablets
Marbofloxacin should not be used in dogs aged less than 12 months or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs with a longer growth period. Not recommended for use in cats aged less than 16 weeks.
Not suitable for infections resulting from strict anaerobes, yeast or fungi.
The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately, especially in young animals.
The fluoroquinolones are known for their potential neurological side effects; cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy.
A low urinary pH could have an inhibitory effect on the activity of Marbofloxacin.
Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of the treatment.
At the therapeutic recommended dosage no severe side effects are to be expected. In particular no lesions of the articular joints were encountered in clinical studies at the recommended dose rate.
Studies in pregnant rats and rabbits showed no side effects on pregnancy. However, no specific studies have been carried out in pregnant cats and dogs.
Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron.) In such cases, the bioavailability may be reduced.
Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.
Do not use Marbocyl P 20mg or Marbocyl P 80mg tablets in cats. For the treatment of this species the Marbocyl P 5mg tablet is available.
Withdrawal periods
Not applicable
Operator warning
People with known hypersensitivity to fluoroquinolones should avoid using this product. In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor. Wear gloves when handling or dividing tablets. Wash hands after use.
2. Marbocyl 10%
Withdrawal periods
Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 36 hours from the last treatment.
Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 6 days from the last treatment. Pigs may be slaughtered for human consumption only after 2 days from the last treatment.
Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.
General precautions: No severe side-effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively. In particular, no lesions of the articular joints are encountered.
Intramuscular or subcutaneous injections are well tolerated although transitory inflammatory lesions without clinical impact can occur at the injection site.
May be used in pregnant and lactating cows and sows.
Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevelance of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
Operator warnings
People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.
Pharmaceutical precautions
1. Marbocyl P 5mg, 20mg, 80mg tablets
Store below 25°C and protect from light.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
2. Marbocyl 10%
Do not store above 25°C and protect from light.
Following withdrawal of the first dose, use the product within 28 days. Any unused material should be discarded.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.
Packaging quantities
1. Marbocyl P 5mg, 20mg, 80mg tablets
Marbofloxacin palatable tablets are packaged in aluminium/aluminium blister packs.
Marbocyl P 5mg 10 blisters of 10 tablets
Marbocyl P 20mg 10 blisters of 10 tablets
Marbocyl P 80mg 12 blisters of 6 tablets
2. Marbocyl 10%
Amber type II glass vials of 20, 50, 100 and 250ml. The vials are closed with a chlorobutyl rubber stopper oversealed within aluminium caps. Each vial is packaged in a cardboard box. Not all pack sizes may be marketed.
Further information
1. Marbocyl P 5mg, 20mg, 80mg tablets
Marbofloxacin is a synthetic bactericidal antimicrobial belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci, Streptococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcesens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Pasteurella spp, Haemophilus spp, Moraxella spp, Pseudomonas spp, Brucella canis) as well as Mycoplasma spp.
Marbofloxacin is not effective against anaerobes, yeasts or fungi.
After oral administration in dogs and cats at the recommended dose of 2 mg/kg, Marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5 microgram/ml within 2 hours. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (<10%), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, digestive tract) it achieves higher concentrations than in plasma. Marbofloxacin is eliminated slowly (t½ß= 14 h in dogs and 10 h in cats) predominately in the active form, in urine (2/3) and faeces (1/3).
2. Marbocyl 10%
ATC Vet code: QJ01MA93
Pharmacodynamic properties:
Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Pasteurella spp, Haemophilus spp, Moraxella spp, Pseudomonas spp) as well as Mycoplasma spp.
Pharmacokinetic properties:
After subcutaneous or intramuscular administration in cattle and intramuscular administration in pigs at the recommended dose of 2mg/kg, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5microgram/ml within less than 1 hour. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (less than 10% in pigs and 30% in cattle), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract) it achieves a higher concentration than in plasma.
In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves (t1/2β = 5-9h) but faster in ruminant cattle (t1/2β = 4-7h) predominantly in the active form in urine (¾ in pre-ruminating calves, ½ in ruminants)
In pigs, marbofloxacin is eliminated slowly (t1/2β = 8-10h) predominantly in the active form in urine (2/3) and faeces (1/3).
Disclaimer
This site has been created by www.MedicAnimal.com for information purposes only. MedicAnimal is a proud retailer of Marbocyl but is not affiliated with or related to the manufacturer of Marbocyl and the contents of this site are neither sponsored or endorsed by the manufacturer of Marbocyl.